Life sciences panel pegs bright spots in Indiana
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
WellPoint Inc.’s now infamous decision to raise rates on individual customers in California as much as 39 percent was apparently made over objections by the company’s California president. Those increases by the Indianapolis-based health insurer were widely blamed for reigniting a dying health reform bill that WellPoint opposed. In an interview with the Los Angeles Times, Leslie Margolin said she worked internally to prevent WellPoint from raising rates so high and, once they did, to scale them back. The newspaper reported that Margolin and others voicing concerns about the size and timing of the hikes were overruled by WellPoint corporate executives. Margolin did not voice concerns about the increases when she was called before the California legislature to explain them, but the Times said she did apologize in a speech at Pepperdine University. WellPoint replaced Margolin last month and she told the Times she was escorted from her office by security guards, without a chance to say farewell to her employees. WellPoint said Margolin’s departure had nothing to with the rate hikes.
Officials in Gov. Mitch Daniels’ administration want to use the Healthy Indiana Plan as the vehicle to expand Medicaid coverage under the new federal health reform law—in spite of Daniels’ earlier comments that the new law would kill the three-year-old plan. According to the Associated Press, Indiana human services chief Anne Murphy sent a letter to the Centers for Medicare and Medicaid Services saying the Healthy Indiana Plan is "the natural vehicle" for expanding Medicaid coverage to Indiana residents in 2014. But when the new health law passed, Daniels described the Healthy Indiana Plan as a "program whose days are numbered" and asked Murphy to begin planning its phaseout.
Northwest Radiology Network PC recently expanded into Anderson by acquiring Madison County Imaging at St. John’s Medical Center and affiliating with Central Indiana Orthopedics of Anderson. Northwest Radiology is now providing its services to St. Vincent Heart Center of Indiana. Both St. John’s and the Heart Center are owned by the St. Vincent Health hospital system, based in Indianapolis.
The complex regulatory process for winning approval of combo medical products is the topic of next week’s Life Sciences Lunch at the Barnes & Thornburg law firm downtown. Gretchen Bowker, an Eli Lilly and Co. alumna and now chief operating officer of Pearl IRB Inc. in Indianapolis, will present, as will Julie Dykstra, a Barnes & Thornburg attorney. The Aug. 17 event, organized by the Indiana Health Industry Forum, costs $10 and starts at 11:30 a.m.
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
To create a disciplined investment strategy, I developed “The Ten Essential Principles of Entrepreneurship You Didn’t
Learn in School.” Over the course of 10 columns, I will feature each of
these essential principles. This is the third installment.
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.
With Eli Lilly, Roche Diagnostics and other large life sciences companies shedding jobs, Indiana needs small
life sciences startups to fill the void. To help such companies, two former Lilly employees are starting an institutional
review board that will help small companies launch clinical trials of their innovative technologies. Pearl IRB,
based in Indianapolis, is run by Lilly alumnae Diana Caldwell and Gretchen Miller Bowker. It is, according to the Indiana
Health Industry Forum, the first commercial institutional review board in the state. That’s significant because such
boards must approve clinical trials before such research on humans can begin. Typically, universities and large hospitals
have institutional review boards, but they are not normally available for researchers not affiliated in some way with those
institutions.
Iraq war veteran Nate Richardson is now using his battlefield experience to launch his own business. His company, Anderson-based
Coeus Technology, developed an antimicrobial liquid it says can be added to military uniforms and equipment
to make them resistant to germs for longer periods of time than current products. The U.S. Army Material Command is currently
testing Coeus’ MonoFoil Technology for its use. But Coeus is also pursuing sales of MonoFoil to civilian users, such
as hospitals and schools. Coeus opened a year ago in Anderson’s Flagship Enterprise Center. It plans to add packing,
filling and research facilities in the next two years, creating 30 to 50 jobs by 2012.
A team of researchers at Purdue University say they’ve found a new marker for prostate cancer that
could replace the prostate-specific antigen (PSA) that is now the leading indicator for the disease. Purdue chemist Graham
Cooks and Purdue oncologist Timothy Ratliff led the team, which found that the compound cholesterol sulfate occurs in prostate
cancer tumors but not in healthy prostate tissue. That stark difference could prove better than PSA, which sometimes appears
at elevated levels in prostates that are inflamed or enlarged, but not cancerous.
The California-based Howard Hughes Medical Institute has awarded $364,000 to more than double Indiana University’s
repository of fruit flies, which have served as the basis of most genetic research for the past century. The Bloomington Drosophila
Stock Center houses 30,000 fruit fly strains and helps develop scientific tools that are used to design new fly strains. The
new grant will allow the stock center to expand to as many as 70,000 fruit fly variants. When the stock center moved from
the California Institute of Technology to Indiana University 25 year ago, it was home to only 1,675 strains.
Indianapolis-based Dow AgroSciences posted a profit of $196 million, up from $140 million in the same quarter
last year, according to Bloomberg News. Second-quarter revenue increased 4 percent, to $1.3 billion, for the unit of Michigan-based
Dow Chemical Co. Company officials credited increased sales for Dow AgroSciences’ herbicides, including some new products,
in spite of weather-related delays.
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
The gains amid economic malaise are impressive, but also unsustainable. Companies can’t continue to grow earnings forever based on cost-cutting.
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
Riley Children’s Foundation received a $1.5 million pledge from the Jeff Gordon Children’s Foundation
to create a cancer research fund. The gift will create a $1 million endowment to fund collaborative research at Riley
Hospital for Children and the Wells Center for Pediatric Research at the Indiana University School of Medicine.
The remaining $500,000 will address immediate research needs at Riley hospital.
Indiana Spine Group will break ground on a 60,000-square-foot facility in Carmel on Aug. 2. The Indianapolis-based
physician practice says it will be able to provide care for any spinal disorder at the center. Located just south of the St.
Vincent Carmel Hospital, the facility will open in the fall of 2011. Indiana Spine Group will relocate its practice, which
is currently near St. Vincent Indianapolis Hospital.
Eli Lilly and Co.’s profits spiked 16 percent in the second quarter to $1.3 billion, or $1.22 per
share, handily beating expectations of Wall Street analysts. Revenue at the Indianapolis-based drugmaker rose 9 percent to
$5.7 billion in the quarter. The company raised its year-end profit forecast by a dime a share, to a range of $4.50 to $4.65,
excluding special items.
Zimmer Holdings Inc. also topped Wall Street expectations for second-quarter profit. The Warsaw-based maker
of orthopedic implants turned a profit of $165.5 million, or 82 cents per share. But it spent $86.5 million on legal claims
and an acquisition. Excluding those costs and special tax savings, the company would have earned $221.2 million, or $1.09
per share—four cents above analysts’ expectations, according to Thomson Reuters. Sales rose 3 percent to $1.06
billion.
Venture dollars for Indiana life sciences companies are still few, but the flow of deals is picking up. Nine Hoosier companies
scored investments totaling $10.4 million during the first six months of the year.
Commuters and truckers could get an all-day headache when Interstate 70 closes in October to allow Eli Lilly and Keep Indianapolis
Beautiful to spruce up part of the city.
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company
developing an enzyme-replacement therapy for disorders of the pancreas.
It may be the health care world’s version of a popularity contest, but it’s still fairly prestigious. It’s
the annual U.S. News & World Report ranking of hospitals. Eleven clinical programs at Clarian Health
and the Indiana University School of Medicine were ranked among the top 50 programs nationally. The rankings
focus on high-volume hospitals and are driven in large part by reputation surveys. No other Indiana-based hospitals were named
to the list. Clarian placed 13th for urology; 14th in gastroenterology; 25th in both geriatrics and ear, nose and throat;
29th in orthopedics; 32nd in lungs; 38th in kidneys; 40th in neurology and cancer; 48th in diabetes; and 49th in cardiology.
In the latest online matchmaking service, Bloomington-based Cook Medical and Indiana University
have created an online portal where medical inventors and health care entrepreneurs can find each other. The website, i2iconnect.org,
allows users to search a database of medical companies by keywords or disease categories. i2iconnect is partly supported by
a stimulus grant from the National Institutes of Health to the Indiana Clinical and Translational Sciences Institute, which
is based in Indianapolis. In 2008, the Indiana Economic Development Corp. tried to start a similar portal for entrepreneurs
of all kinds.
Indianapolis-based BioCrossroads, a life sciences business development group, received a $1.25 million grant
from the Richard M. Fairbanks Foundation, also based in Indianapolis. Fairbanks gave BioCrossroads $2.5 million to fund various
educational and public health efforts.
Eli Lilly and Co. told employees July 15 that it’s cutting 340 information technology positions in
Indiana as part of its march toward 5,500 job cuts by the end of 2011. The Indianapolis-based drugmaker eliminated 140 IT
jobs in June through retirements, resignations and some cuts. Another 115 cuts will be made this month, and the remainder
by the end of the year, according to an e-mail from Janice Chavers, a Lilly spokeswoman. All displaced workers will get a
few months to find another job within Lilly, although those opportunities are few. Workers who leave Lilly will receive severance
based on their pay grade and time served with the company. Lilly employs about 1,250 IT workers in the United States.
Three Indianapolis hospital systems were named “most Wired” hospitals by Hospital & Health Networks
magazine. Clarian Health, Community Health Network and the Roudebush Veterans Affairs Medical Center
all made the list of the top 100 hospital systems in the country using information technology to boost quality, customer service,
safety and business operations.
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
Medical device maker Biomet Inc. plans an expansion of its northern Indiana facilities that could add about
280 jobs, according to the Associated Press. Company officials have discussed the plan with Kosciusko County officials as
they've sought tax breaks on the $26 million project. Biomet attorney Richard Helm says the expansion in Warsaw would
retain about 80 jobs and lead to some manufacturing being moved there from New Jersey. The project would also expand Biomet’s
Warsaw distribution center.
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality
division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on
its bestselling drugs. The Indianapolis-based drugmaker’s latest move will cut nearly 5 percent of its 3,600-person
manufacturing work force in the United States. Lilly will ask for voluntary departures, but it also will eliminate the jobs
of others involuntarily. Some jobs have already been eliminated through attrition. Lilly has announced nearly 2,000 job cuts
toward its goal of 5,500 cuts, which the company set in September. The company is also trying to eliminate $1 billion in annual
expenses by the end of 2011. At that time, it hopes to have a worldwide staff of about 35,000. It currently employs 12,400
in Indiana.
Hundreds of patients will be shifted from Indiana's state psychiatric hospitals into community-based care under a plan
that officials say will eliminate more than 500 jobs, according to the Associated Press. The biggest changes and the layoffs
will come at the Logansport and Richmond state hospitals, while units at the Evansville and Madison hospitals will be converted
to care for those with serious mental illnesses. The moves by the Indiana Family and Social Services Adminstration are expected
to reduce the number of patients at the six state hospitals by about 30 percent and save $15 million a year. The Logansport
State Hospital will have 355 of its 900 workers laid off and 80 vacant positions eliminated. The Richmond
State Hospital will lose 106 of its 600 workers.
A medical device company is seeking a property-tax abatement to offset costs associated with a $1.1 million expansion of
its facility at 3735 N. Arlington Ave. in Indianapolis. New York-based Greatbatch Medical Inc. expects to
create eight jobs at an average wage of $12.75 an hour and retain 146 jobs at an average wage of $14 an hour, according to
the abatement request. Greatbatch specializes in cardiovascular products but is expanding into the orthopedics market, which
is prompting the expansion, the company said.